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Abstract
Venezuelan equine encephalitis virus replicon particles (VRP) function as an effective systemic,
cellular and mucosal adjuvant when codelivered with antigen, and show promise for use as a
component in new and existing human vaccine formulations. We show here that VRP are effective
at low dose and by intramuscular delivery, two useful features for implementation of VRP as a vaccine
adjuvant. In mice receiving a prime and boost with antigen, we found that VRP are required in prime
only to produce a full adjuvant effect. This outcome indicates that the events triggered during prime
with VRP are sufficient to establish the nature and magnitude of the immune response to a second
exposure to antigen. Events induced by VRP in the draining lymph node after prime include robust
secretion of many inflammatory cytokines, upregulation of CD69 on leukocytes, and increased
cellularity, with a disproportionate increase of a cell population expressing CD11c, CD11b, and
F4/80. We show that antigen delivered 24 hours after administration of VRP does not benefit from
an adjuvant effect, indicating that the events which are critical to VRP-mediated adjuvant activity
occur within the first 24 hours. Further studies of the events induced by VRP will help elucidate the
mechanism of VRP adjuvant activity and will advance the safe implementation of this adjuvant in
human vaccines.
1. Introduction
It is a challenge of modern vaccine development to achieve a robust immune response against
weakly immunogenic targets such as a subunit vaccines [1,2]. Such a result can be achieved
by inclusion of an adjuvant, which augments the immune response to codelivered antigen [3]
New adjuvants which are safe and potent are needed for the next generation of vaccines.
Furthermore, induction of mucosal immunity by an adjuvant should improve protection against
pathogens which enter the body by a mucosal route [4,5]. Although mucosal immunity has
traditionally been generated in response to a mucosally delivered antigen, it is also possible to
generate a mucosal immune response by parenteral delivery of antigen under the right
conditions [6–16], including codelivery of replicons from the Venezuelan equine encephalitis
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virus (VEE) [17]. VEE is a positive sense alphavirus whose RNA genome encodes four non-
structural replicase proteins (nsPs), followed by an internal promoter (26S) which controls the
transcription of a subgenomic mRNA encoding the virion structural proteins. The adjuvant
qualities of this virus were first identified forty years ago, when it was shown that VEE virus
inoculation enhanced the immune response to antigen [18,19]. VEE replicon particles (VRP)
contain a truncated VEE genome lacking the sequence encoding the structural proteins but
retaining the information for the viral replication machinery [20]. Once assembled, VRP are
infectious for a first round of replication but cannot further propagate to other cells. While VRP
were first developed for their ability to express a foreign immunogen encoded under the control
of the 26S promoter [20], VRP which encode no foreign genes act as a humoral, cellular and
mucosal adjuvant when co-delivered with a soluble antigen [17,21]. VRP can increase
protection against norovirus challenge when used as an adjuvant with a murine norovirus
subunit vaccine [22]. In non-human primates, codelivery of VRP with a seasonal flu vaccine
significantly improved protection upon subsequent homotypic intranasal challenge (C. J.
Miller, personal communication). These findings demonstrate the potential for VRP as an
adjuvant in human vaccines. Here we attempt to better understand the mechanism by which
VRP enhance the immune response.
VRP mediated adjuvant activity most likely involves the activation of an innate immune
response, triggered by VRP infection or replication, as evidenced by induction of dendritic cell
(DC) maturation and secretion of interferons and other cytokines in response to VRP infection
[23,24]. In the work reported here, we characterize the efficacy of VRP as an adjuvant in a
mouse model and find that VRP are necessary only in the initial priming injection in order to
achieve a strong adjuvant effect. We further demonstrate the presence of a rapid inflammatory
response triggered by VRP, which is indicative of the activation of innate immunity. A better
understanding of these early events after VRP injection should help to determine the pathways
which are initiated to produce enhanced systemic, mucosal, and cellular immune responses.
2. Materials and Methods
2.1. VEE Replicon Particles
Production and packaging of VRP have been previously described [20,25]. Briefly, VRP are
packaged into functional particles by electroporation of BHK-21 cells with the replicon genome
along with two helper RNAs. The helper RNAs produce the structural proteins in trans but lack
the cis-acting packaging sequence, so that only the replicon RNA is incorporated into the viral
particles. All replicon particles used in this study were packaged in the wild-type (V3000)
envelope [26]. Three VRP genomes were used. VRP-GFP encodes the sequence for GFP under
the control of the 26S promoter. VRP16M contains the viral nonstructural genes, 16 nt of VEE
sequence downstream of the 26 mRNA transcription start site, an inserted 43-nt multiple
cloning site, and the 118-nt 3’UTR. VRP(−5) contains the viral nonstructural genes but is
deleted for the region between the nsP4 stop codon (5 nts before 26S mRNA transcription start
site) and the beginning of the 118-nt 3’ UTR. Both VRP genomes contain all of the known cis-
acting signals for RNA replication. The subgenomic mRNA promoter in VRP16M is predicted
to program the synthesis of a small, noncoding 3’ polyadenylated RNA of 177 nts, but VRP
(−5) lacks a functional promoter for subgenomic RNA transcription. After purification, the
absence of detectable replication-competent virus was confirmed by cytopathic effect assay,
and VRP were titered by infection of BHK-21 cells as measured by immunofluorescent staining
of VEE non-structural proteins. VRP genome equivalents (GE) were determined by RNA
extraction with an Ambion MagMAX Viral RNA Isolation Kit followed by real time PCR
using nsP1-specific primers and probe as previously described [27]. The ratio of VRP GE to
BHK infectious unit (IU) was approximately 103.
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2.2. Mice and Immunizations
Six to eight week old female Balb/c or C57Bl/6 mice were purchased from Charles River and
were housed at the University of North Carolina Division of Laboratory Animal Medicine
animal facility according to protocols approved by the Institutional Animal Care and Use
Committee. Balb/c mice were used for all experiments except for assay of T cell responses to
OVA, for which C57Bl/6 mice were used. Mice were injected in the rear footpad or by
intramuscular delivery on week 0 and 4 with chicken egg albumin (OVA) (Sigma) (10 or 100
µg) alone or OVA mixed with the stated infectious units (IU) of VRP, as described in the text.
Endotoxin in the OVA preparation was reduced below the level of detection by phase separation
using Triton X-114 [28]. For some experiments, OVA was conjugated to Alexa Fluor 488 using
the Alexa Fluor 488 Protein Labeling kit (Invitrogen).
2.3 Analysis of OVA-specific IgG and IgA in serum and fecal extracts
Serum was collected from mice 3 weeks after boost. For isolation of fecal extracts, fecal pellets
were collected 10 days after boost and vortexed at 4°C at 0.2 g/ml in PBS containing 10% goat
serum and 1× protease inhibitors (Roche) until pellets were disrupted. Samples were
centrifuged, and supernatants were filtered through 0.22 µm filters OVA-specific IgG and IgA
antibodies were detected by ELISA on 96-well high binding plates (Thermo Scientific) coated
with 10 µg/ml OVA in PBS. Sera and fecal extracts were added to plates in serial dilutions.
OVA-specific antibodies were detected with horseradish peroxidase conjugated antibodies
specific for mouse IgG (Sigma) or mouse-IgA (Southern Biotechnology) followed by addition
of o-phenylenediamine dihydrochloride substrate (Sigma) for 30 minutes. Endpoint titers were
determined as the last sample dilution that generated an OD450 reading of greater than 0.2. For
determination of total IgA levels in fecal extracts, 96 well plates were coated with 5 µg/ml
rabbit anti-mouse IgA (Invitrogen), ELISAs performed as above, and a standard curve
generated from dilutions of purified murine IgA (Sigma). This standard curve was used to
determine the concentration of both OVA-specific and total IgA in fecal extracts.
2.4. Preparation of DLN Extracts for Multiplex Analysis
Mice were immunized in the footpad with either 10 µg OVA, or OVA + VRP. Six hours after
immunizations in both footpads, the draining popliteal lymph nodes from each mouse were
harvested, combined and placed in 200 µl of PBS containing 1× protease inhibitors (Roche).
The lymph nodes were mechanically homogenized with a pestle, followed by centrifugation
at 4°C. Supernatant was transferred to another tube and frozen on dry ice. Cytokine levels in
the samples were analyzed by a Luminex-based assay (Milliplex) purchased from Millipore.
For one experiment, levels of 32 cytokines were tested using the Milliplex MAP Mouse
Cytokine/Chemokine Premixed 32 Plex (Millipore). Samples were analyzed by Millipore, and
30 cytokines were successfully detected. A 10-plex assay detected G-CSF, GM-CSF IFN-γ,
IL-5, IL-6, IL-12p40, IP-10, MIG, MIP-1β, and TNF and was performed by the Clinical
Proteomics Laboratory at Thurston Arthritis Research Center, University of North Carolina.
Multianalyte profiling was performed on the Luminex-100 system and the XY Platform
(Luminex Corporation, Austin, TX). Calibration microspheres for classification and reporter
readings, as well as sheath fluid were also from Luminex Corporation. Fluorescence data was
acquired by MasterPlex™ CT 1.2 software (MiraiBio, Alameda, CA). Data analysis was
performed using the MasterPlex QT 4.0 system (MiraiBio, Alameda, CA). A five-parameter
regression formula was used to calculate the sample concentrations from the standard curves.
Cytokines which were undetectable were assigned a value of half of the lowest limit of detection
as determined by the standard curve. Cytokine levels which exceeded the standard curve were
assigned a value of 10,000 pg/ml.
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2.5. Surface and intracellular staining of cells from spleen and lymph node
Spleens or draining popliteal or iliac lymph nodes were harvested at the time points indicated,
homogenized through 40 µm cell strainers, and cells counted. For intracellular IFN-γ staining,
spleen cells were cultured in RPMI-10 containing brefeldin A (GolgiPlug, BD Biosciences)
either in the presence of OVA peptide (SIINFEKL) or an irrelevant peptide (2 µg/ml) for 5 h
at 37°. Cells were washed and stained at 4°C for desired surface receptors with fluorochrome-
conjugated antibodies specific for CD3, CD8, CD11c, CD19, and CD69 (eBioscience) in 1%
BSA/PBS. Brefeldin A was included in this step if cells were to be stained for IFN-γ. Cells
were fixed in 2% paraformaldehyde for 15 min at room temperature. For IFN-γ staining, fixed
cells were washed and permeabilized in staining buffer containing 0.5% saponin and stained
with anti-IFN-γ (eBioscience) at 4°C. Cells were then washed with saponin buffer and analyzed
on an Accuri flow cytometer.
3. Results
3.1. VRP with a minimum genome lacking a complete 26S subgenomic RNA promoter are an
effective adjuvant by intramuscular delivery
In initial studies of its adjuvant properties, the VRP which were used, designated VRP16M,
contained a 59 nt non-coding sequence and a 118 nt 3’ UTR after the 26S promoter start site
(Fig 1A) [17]. UV inactivation of the VRP RNA indicated that transcription and/or replication
of the VRP genome is necessary for its function as an adjuvant [17], but it was unknown if the
26S promoter played a role. On a molar basis the 26S subgenomic RNA is present at ten times
the amount of genomic RNA [20], and this robust transcription may augment or inhibit the
VRP adjuvant effect. We addressed this uncertainty by comparing the adjuvant effect of two
different VRP genomes: VRP16M or a new VRP genome named VRP(−5) which contains a
deletion in the core 26S subgenomic promoter and is genetically incapable of producing a
subgenomic RNA (Fig 1A). Mice were primed and boosted with OVA alone or OVA in the
presence of a low dose of VRP16M or VRP(−5) (103 IU, which corresponds to 106 GE). (VRP
IU are based on in vitro infection of BHK-21 cells; in vivo infectivity is undefined.) After the
boost we measured anti-OVA IgG in the serum and anti-OVA IgA in fecal extracts. Both VRP
genomes significantly increased antibody responses compared to OVA alone (Fig1 B,C), with
the VRP(−5) genome inducing a significantly stronger mucosal IgA response. These results
show clearly that the 26S promoter is not required for the adjuvant effect induced by VRP, so
for all subsequent experiments we used the VRP(−5) genome, which will be referred to as
simply VRP for the rest of this report.
In all previous studies of VRP adjuvant activity the VRP were injected into the footpad, but
because this is an impractical route for human vaccines, we assessed whether VRP would be
effective by intramuscular (i.m.) delivery. Mice were primed and boosted with OVA and VRP
(105 IU) in the footpad or i.m. Anti-OVA serum IgG and fecal IgA titers were significantly
increased by both routes of delivery (Fig1 D,E), indicating that i.m. delivery of VRP is just as
effective as footpad delivery.
3.2. VRP are an effective adjuvant at a wide range of doses
Data shown in Figure 1 demonstrate that VRP injected into the footpad are an effective adjuvant
at a relatively low dose (103 IU). To evaluate the efficacy of lower doses of VRP delivered
i.m., we tested the effect of VRP on anti-OVA immunity after i.m. injection in Balb/c mice
using a range of VRP doses between 102 and 105 IU (105–108 GE). Titers of anti-OVA IgG
in the serum had a clear dose-response, and all tested doses of VRP significantly increased the
anti-OVA titers relative to mice immunized with OVA alone (Fig 2A). The mucosal response
measured in the fecal extracts demonstrated clear induction of anti-OVA IgA antibodies at all
tested VRP doses, with the strongest response at ≥ 104 IU (Fig 2B).
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To examine the VRP dose effect on T cell responses, we primed and boosted C57Bl/6 mice
i.m. with OVA alone or in the presence of increasing doses of VRP. This mouse strain was
used because T cell-reactive OVA peptides are known for this mouse, and it was previously
shown that the VRP adjuvant effect is intact in this strain [21]. The dose of OVA used (100
µg) was based on the previous finding that this higher dose was required for a detectable T cell
response (25). After boost, spleen cells harvested from these mice were incubated in vitro with
a CD8-specific OVA peptide, and IFN-γ production was measured by intracellular staining
and flow cytometric analysis. The percent of detected OVA-responsive CD8 T cells slightly
increased with increasing VRP dose, and the response increased significantly at the highest
dose of VRP (105 IU) (Fig 3).
3.3. VRP adjuvant activity requires the presence of VRP in the prime but not in the boost
Previous data suggested that the mucosal immunity induced by parenteral delivery of VRP
may be due to the induction of a mucosal-like environment in the draining lymph node [29].
It is therefore possible that there are long-term effects in the lymph node after prime with VRP
which affect the immune response during boost. In addition, it was unknown whether VRP
play a more important role during prime or boost, or if both are equally important. We addressed
these questions in mice which received a prime and boost with OVA in the footpad. These
mice were divided into groups which received no VRP, VRP in prime only, VRP in boost only,
VRP in both prime and boost, or VRP and OVA in the contralateral footpad during boost. We
performed these studies in the footpad instead of i.m., so that the injection would drain to a
single lymph node, focusing any effects. A low VRP dose (103 IU) was used to minimize
possible effects of VRP in other lymph nodes. Evaluation of anti-OVA IgG in the serum and
IgA in fecal extracts demonstrates a comparable adjuvant effect in mice receiving the boost in
the same or contralateral footpad as in prime (Fig 4 A,B). The OVA-specific IgG titer was
similarly increased when VRP was included in prime only (Fig 4A). However, when VRP was
present only in the boost, the IgG titer was increased but to a significantly lower level. A more
dramatic effect was observed for fecal anti-OVA IgA. Mice receiving VRP only during the
boost had no detectable anti-OVA IgA, but addition of VRP to the prime only induced an IgA
response comparable to that seen in mice immunized with VRP during both prime and boost
(Fig 4B). After prime with antigen and VRP, we do not observe any mucosal response without
an antigen boost (data not shown), so it is apparent that boost with antigen is still required to
generate an IgA response.
3.4. Several inflammatory cytokines are rapidly induced in the draining lymph node after
immunization with VRP
Previous studies of VRP activity have evaluated events in the draining lymph node after boost
[29]. Since the events which occur during prime are clearly crucial for the VRP adjuvant
activity (Fig 4), we examined the cytokine environment in the draining lymph node 6 hours
after prime with VRP by multiplex analysis. We again used footpad rather than intramuscular
injection because this route allows us to focus our analysis on a single lymph node. We first
measured levels of 30 cytokines in draining popliteal lymph nodes harvested 6 hours after
footpad injection with OVA (10µg) or with OVA combined with 104 IU VRP. In VRP-injected
mice we observed a significant increase in 18 of the 30 measured cytokines (Table 1). Based
on the collected data, we selected a panel of 10 cytokines, 9 of which had a large fold increase
in response to VRP, and one negative control (IL-12p40). We assessed those cytokine levels
after injection of OVA alone or OVA with a range of VRP doses between 101 and 105 IU. Six
hours after immunization, levels of 10 cytokines in lymph node homogenates were measured
by a multiplex assay. Of the analyzed factors, four (G-CSF, IFN-γ, IL-6 and MIP-1β) were
upregulated to relatively high levels at VRP doses of 103 IU and above (Fig 5A). Three other
cytokines (GM-CSF, IL-5, and TNF) were upregulated at a similar range of VRP doses,
although the absolute levels of cytokines were lower than those shown in Figure 5A, and are
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shown separately for clarity (Fig 5B). The chemokines MIG and IP-10 were strongly
upregulated from undetectable levels to levels above the maximum limits of the assay at all
doses of VRP greater than 101 IU, while IL-12p40 was not upregulated at all (data not shown).
3.5. Increased cellularity and leukocyte activation in the lymph node is dose responsive
Because VRP clearly induce rapid inflammation in the draining lymph node, we evaluated how
the VRP dose affects leukocyte activation and recruitment to the lymph node. It has been
previously reported that the cellularity of the draining lymph node dramatically increases after
boost with VRP [29]. Here we examined the impact on the lymph node after prime by injection
of a range of doses of VRP between 101 and 105 IU into the footpads of mice. Draining popliteal
lymph nodes were harvested after 6 or 24 hours, and cells were counted and stained with
antibodies specific for cell surface markers. Lymph node cellularity was not changed during
the first 6 hours post VRP inoculation (data not shown), but after 24 hours lymph node
cellularity was significantly increased when compared to diluent alone at VRP doses of 102
IU and above (Fig 6A). It was previously observed that after boost with VRP there is a
disproportionate increase in the number of CD11c+CD11b+ cells in the draining lymph node
[29]. Our data show that this is true after prime as well, and we further found that the >80%
of these cells express F4/80 in addition to CD11c and CD11b. This population constituted a
small percentage of the cells in the lymph node in uninjected mice and was significantly
increased 24 hours after prime with a VRP dose of 102 IU or greater (Fig 6D). We also examined
CD69, an early activation marker on leukocytes [30,31], which has the function of suppressing
egress of activated cells from the lymph node [32]. At 6 hours after prime with VRP, CD69
was increased on the total live cell population in mice injected with 103 IU or greater (Fig 6B),
similar to the range of VRP doses that upregulated cytokines after 6 hours (Fig 5). By 24 hours,
CD69 was upregulated in a dose-responsive manner at all tested VRP doses, and appeared to
plateau starting at 104 IU (Fig 6C). The increase in CD69 was not specific to any particular
cell type, as T cells, B cells, DCs, and macrophages were all similarly affected (data not shown).
Because the response to VRP may differ somewhat following i.m. injection, we assessed the
amount of VRP present in the draining lymph node following footpad or i.m. gastrocnemius
injection of VRP-GFP. After 16 hours, we harvested various lymph nodes and detected GFP-
positive VRP-infected cells by flow cytometry. After footpad injection, VRP-infected cells
were detected almost exclusively in the popliteal lymph node. After i.m. injection, small
numbers of GFP-positive cells were observed in the iliac lymph nodes (Fig 6E), but not the
inguinal lymph nodes (not shown). Although fewer infected cells were detected following i.m.
injection, CD69 levels were elevated in the iliac lymph nodes and much less so in the popliteal
lymph node (Fig 6F).
3.6. The immunity-enhancing environment induced by VRP lasts less than 24 hours
We hypothesize that inflammation induced by VRP in the draining lymph node plays an
important role in the observed adjuvant effect, but it was unknown if antigen must be delivered
at the same time as VRP to be affected by this inflammatory environment. To address this
question we inoculated mice in the footpad with VRP at time 0 and injected those mice with
OVA in the same footpad at the same time or 24 hours before or after the VRP injection. After
4 weeks the mice were boosted in the same way. Anti-OVA IgG in the serum was not
significantly increased in mice injected with OVA 24 hours before or after VRP (Fig 7A). Fecal
anti-OVA IgA was significantly upregulated when OVA was delivered before VRP, although
to a lesser degree than when VRP and OVA were delivered together (Fig 7B). In contrast,
injection of OVA 24 hours after VRP resulted in no induction of fecal anti-OVA IgA.
It is possible that this poor mucosal response to OVA delivered after VRP is due not to the
kinetics of the VRP-induced immune response to antigen, but rather to VRP-triggered
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alteration of antigen transport to the draining lymph node. We assessed this possibility by
immunizing mice in the footpad with OVA labeled with Alexa Fluor 488, either alone, in the
presence of VRP, or in mice injected in the footpad 24 hours earlier with VRP. After 6 hours
levels of OVA-positive cells in the draining lymph node were detected by flow cytometry. We
found that the level of OVA-containing cells in the lymph node was unaffected by coinjection
with VRP and was in fact increased in mice injected with VRP 24 hours earlier (Fig 7C). Based
on this outcome we conclude that altered antigen transport is unlikely to play a significant role
in the response to antigen delivered after VRP.
4. Discussion
The findings presented here further demonstrate the potency of VRP as a vaccine adjuvant,
reveal new indicators of VRP activity, and will help to define optimal conditions for use of
this adjuvant. Comparison of VRP genomes that either contain (VRP16M) or lack (VRP(−5))
the 26S promoter revealed that the promoter does not contribute to adjuvant activity. The
promoter may in fact reduce the adjuvant effect, as mucosal anti-OVA IgA levels were
increased when VRP(−5) was used as an adjuvant. One explanation for this outcome is that
nsP gene amplification is necessary for adjuvant activity and may be reduced by the highly
active 26S promoter competing for RNA synthetic machinery. Another asset of the VRP(−5)
genome is that it may reduce the already slim probability of producing a propagation-competent
virus during VRP assembly, improving safety. During production of VRP, the unlikely event
of nonhomologous RNA-RNA recombination between replicon and both helper RNAs in the
packaging cell could result in a recombinant, propagation-competent genome containing the
nsP genes linked to the structural genes downstream of their own 26S promoters [20,25].
Because the VRP(−5) genome contains no sequence between the end of nsP4 and the start of
the 3’UTR, there is very little sequence in which a productive recombination can occur.
Preliminary data has shown clearly reduced incidence of single helper RNA recombinants
produced by VRP(−5) (data not shown).
Data shown here demonstrate that i.m. VRP injection, a routine route for human vaccination,
is just as effective as footpad injection in the mouse, which was the only route previously tested.
We have further shown that humoral adjuvant activity of VRP is maintained at much lower
doses than had previously been tested. The practical value of this finding is that use of low
doses of VRP in human (or veterinary) vaccines will make this adjuvant more cost-effective.
In addition, the need for only a small dose of VRP in a vaccine should help to further minimize
risks associated with VRP, namely generation of propagation competent virus and induction
of anti-VEE immunity. We did not observe a significant augmentation of the CD8 T cell
response at any VRP dose below 105 IU. Either higher VRP doses are required to enhance
cellular responses, or our assay of cellular immunity is less sensitive than that for humoral
immunity. It will be valuable to examine whether CD8-dependent protection from pathogens
can be achieved at lower VRP doses.
We have confirmed and extended previous data demonstrating that VRP injection generates
an inflammatory environment in the draining lymph node [29]. By multiplex analysis we
observed dose-dependent upregulation of many inflammatory cytokines and chemokines in
the draining lymph node following injection of VRP, indicative of an innate immune response.
These results are generally consistent with the cytokines previously observed after boost with
VRP [29]. IL-6 and TNF secretion have previously been demonstrated in VRP-infected DCs
in vitro [23], and most of the other cytokines measured here can also be secreted by myeloid
cells such as macrophages and DCs, including G-CSF, GM-CSF, IP-10, MIG, MIP-1β, and
IFN-γ[33–38], while NK cells are another likely source of IFN-γ [39]. It should also be noted
that type 1 interferons, which were not tested in this assay but are a central marker of innate
immune induction, have been observed in mouse serum within 6 hours of VRP injection
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(unpublished results). In addition to cytokine secretion, we identified many other indicators of
innate immune activation in the draining lymph node such as rapid upregulation of CD69 and
increased lymph node size and cellularity, with a disproportionate increase in monocytic cells
which express the surface receptors CD11b, CD11c, and F4/80. All of these effects were dose-
responsive. CD69 may play a role in the observed increase in lymph node cellularity by
preventing lymph node egress of CD69-expressing cells [32]. Similar CD69 upregulation has
been observed on various leukocyte subsets following infection with the VEE virus [40], or
injection of other adjuvants such as Poly(I:C) [32], CpG [41], and U1 RNA [42], and it is likely
upregulated in response to inflammatory cytokines such as those observed here [30,31,43]. We
hypothesize that VRP stimulation of pattern recognition receptors triggers secretion of such
cytokines in the draining lymph node, which in turn drive leukocyte recruitment and activation,
resulting in enhanced T cell and B cell memory.
Footpad and i.m. VRP injection are effective at similar doses, yet we identified many more
VRP-infected cells in draining lymph nodes following footpad injection. Even so, after i.m.
injection we observed robust upregulation of CD69 in the iliac lymph nodes, suggesting that
lymph node activity is still relevant by this route. It may simply be that even a small number
of VRP-infected cells are sufficient to augment immune activity in the lymph node. It is also
possible that after i.m. injection not all VRP-infected lymph node cells were detected due to
trafficking of VRP to multiple lymph nodes, some of which were not easily isolated, such as
deep inguinal nodes. Alternately, VRP may activate uninfected macrophages and DCs in the
muscle which then migrate to the lymph nodes and drive an inflammatory, immune-enhancing
response.
If the inflammatory environment induced in the draining lymph node by VRP is driving the
adjuvant effect, then it is important to know how long this immune enhancing environment
effects persists. The observed absence of adjuvant effect for antigen injected 24 hours after
VRP indicates that the immune-enhancing events triggered by VRP have come and gone within
the first 24 hours. We also observe no role for long term VRP-induced changes in the draining
lymph node, as boost need not occur in the same site as prime. This result suggests that VRP-
containing human vaccines will not cause immunity against irrelevant antigens introduced
≥24hrs after immunization, an important safety consideration. Interestingly, we found that VRP
will enhance immunity to antigen already present at the injection site, for a mucosal immune
response was generated against OVA injected 24 hours before VRP.
The finding that VRP are dispensable during antigen boost reveals that events which occur
during a VRP-containing primary immunization are sufficient to set the stage for an enhanced
immune response upon subsequent exposure to the same antigen. It may simply be that strong
T and B cell memory are established during prime with the help of the innate immune activation
in response to VRP, so during boost further innate immune-driven costimulation becomes
unnecessary [44,45] A similar requirement for the presence of adjuvant only in prime has been
occasionally demonstrated [6,46,47], but it is unclear whether this holds true for most
adjuvants, or only a unique subset. In our adjuvant model, mucosal immunity is not observed
after prime with antigen and VRP (data not shown), but can be detected only after boost with
antigen (with or without VRP). It therefore appears that after immunization with VRP the nature
of the immune response to co-delivered antigen has been fully established, and boost is required
simply for further stimulation of lymphocyte expansion and antibody production.
Alternatively, it is possible that the lack of VRP activity in boost is due to anti-VRP immunity
generated during prime, but this is unlikely, as anti-VRP immunity is not detected after a single
VRP injection [20].
The many inflammatory events which occur after VRP injection will not only inform our
studies of the VRP adjuvant mechanism, but should also be useful as indicators of adjuvant
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activity. We have shown that these effects increase proportionally to dose, so it should be
possible to correlate defined inflammatory events with successful induction of various aspects
of the immune response. These inflammatory indicators may be used as clinical markers of
adjuvant efficacy, and could be tracked in serum in clinical trials, serving as a link between
animal and human studies. We believe that the potential of VRP as a human vaccine adjuvant
is considerable, as VRP have a clean record of safety [48,49], robust activity, and simple
formulation. Previous studies have demonstrated that VRP can induce VEE-specific immunity
[20,50], but it remains uncertain whether such immunity will limit activity of VRP in
subsequent immunizations. While this remains a concern which must be addressed, we have
demonstrated here that VRP are effective at low doses which can be limited to use in the primary
immunization. By using limited amounts of VRP in this way we can reduce anti-VEE titers,
helping to alleviate this concern. These advantages, combined with the ability of VRP to induce
mucosal immunity, may make VRP a safe and promising adjuvant to improve new and existing
vaccines.
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VRP adjuvant activity is intact when using intramuscular delivery of VRP which lack the 26S
promoter. (A) The VEE parental genome contains sequence for four nsPs and a 26S promoter
followed by a polyprotein which is processed to produce the capsid and two envelope
glycoproteins (C, E1, E2). The VRP genome lacks the structural protein sequences. VRP16M
contains 16 nucleotides and a multiple cloning site (MCS) after the 26S promoter, while VRP
(−5) lacks the sequence between the nsP4 gene and the 3’UTR, including the 26S start site. (B
& C) Balb/c mice were primed and boosted in the footpad with OVA (10 µg) alone or in a
coinjection with VRP16M or VRP(−5) (103 IU, ≈106 GE). (D & E) For analysis of the route
of immunization, Balb/c mice were primed and boosted either by footpad or intramuscular
injection with OVA (10 µg) in the absence or presence of VRP(−5) (105 IU, ≈108 GE). Levels
of anti-OVA IgG in the serum (B & D) and anti-OVA IgA in fecal extracts (C & E) were
determined by ELISA. Six mice per group were injected, and values represent the geometric
mean +/− SEM. Statistical significance (p<0.05) was determined by t test relative to
immunoglobulin levels detected for mice injected with OVA only, unless otherwise indicated.
Similar results were achieved in two separate experiments.
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VRP are an effective adjuvant at a wide range of doses. Balb/c mice were primed and boosted
i.m. with OVA (10 µg) in the absence or presence of the indicated dose (infectious units) of
VRP (1 IU ≈ 103 GE). After boost, anti-OVA serum IgG (A) and anti-OVA fecal IgA (B) were
measured by ELISA. Six mice per group were injected, and values represent the geometric
mean +/− SEM. Statistical significance (p<0.05) was determined by t test relative to OVA only.
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C57Bl/6 mice were primed and boosted i.m. with OVA (10 µg) alone or in coinjections with
the indicated VRP dose (1 IU ≈ 103 GE). 8 days after boost, spleens were harvested and
4×106 spleen cells incubated with OVA peptide (2 µg/ml) or an irrelevant peptide. Spleens
from uninjected mice were assayed as well. After 5 hours, surface CD8 and intracellular IFN-
γ were stained and measured by flow cytometry. There was no response to irrelevant peptide.
For OVA stimulated cells, IFN-γ-positive CD8 T cells are shown. Six mice per group were
injected, and statistical significance (p<0.05) was determined by t test relative to OVA only.
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VRP are required only during prime to induce a mucosal adjuvant effect. Balb/c mice were
primed in the footpad with OVA (10 µg) alone or in a coinjection with VRP (103 IU, ≈106
GE). Mice were boosted in the same way either in the same or contralateral footpad. Other
mice were primed and boosted with OVA, but received VRP only in prime, or in boost.After
boost, anti-OVA serum IgG (A) and anti-OVA fecal IgA (B) were measured by ELISA. Six
mice per group were injected, and values represent the geometric mean +/− SEM. Statistical
significance (p<0.05) was determined by t test relative to OVA only, or as indicated. Similar
results were achieved in two separate experiments.
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VRP trigger rapid secretion of inflammatory cytokines in the draining lymph node. Balb/c mice
were injected in the footpad with OVA (10µg) alone or in the presence of VRP at the indicated
dose (1 IU ≈ 103 GE). After 6 hours the draining popliteal lymph node was harvested,
homogenized, and cytokine levels in the homogenate analyzed by multiplex analysis. Values
represent the geometric mean +/− SEM. For cytokines which were undetectable, a value of
one half of the lower limit of detection was assigned. The maximum limit of detection was
10,000 pg/ml. Cytokines detected at levels above 1000 pg/ml (A) are shown separately from
those detected at lower levels (B). Four mice per group were injected, and values represent the
geometric mean +/− SEM.
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VRP-induced inflammation in the draining lymph node is dose responsive. Balb/c mice were
injected with diluent or VRP at the indicated dose (1 IU ≈ 103 GE). Draining lymph nodes
were harvested after 6 or 24 hours post injection (hpi), homogenized, and cells counted (A).
Expression of CD11b, CD11c, F4/80 and CD69 was identified by fluorescent antibody staining
and analysis by flow cytometry (B–D). Results were gated on live cells as determined by
forward and side scatter, and receptor expression is shown as a percent of total live cells. Four
mice per group were injected, and values represent the geometric mean +/− SEM. Statistical
significance (p<0.05) was determined by t test relative to diluent. Similar results were achieved
in at least two separate experiments.
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VRP-induced inflammation does not affect the mucosal response to antigens delivered 24 hours
after VRP. Balb/c mice were primed and boosted with OVA alone or in the presence of VRP
(105 IU, ≈108 GE). VRP was delivered at time 0 and OVA was delivered either at time 0, −24
hours, or +24 hours, for both prime and boost. After boost, anti-OVA serum IgG (A) and anti-
OVA fecal IgA (B) were measured by ELISA. In (C), mice were injected in the footpad with
OVA (0.5 ug) conjugated to Alexa-Fluor-488. In some mice, VRP (105 IU, ≈108 GE) was
injected with OVA, and some mice were injected with VRP (105 IU, ≈108 GE) 24 hours before
OVA injection. After 6 hours the draining popliteal lymph node was harvested, homogenized,
and analyzed by flow cytometry for the presence of OVA-positive cells, based on detection of
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cells containing Alexa Fluor-488. Six mice per group were injected, and values represent the
geometric mean +/− SEM. Statistical significance (p<0.05) was determined by t test relative
to OVA only.
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Table 1
Cytokine levels in draining lymph node homogenate 6 hours post inoculation (pg/ml ± SEM)
OVA a OVA + VRP a
Eotaxin 190 ± 34 412 ± 97
G-CSF 115 ± 26 1918 ± 191 *
GM-CSF 2 ± 0 293 ± 37 *
M-CSF 24 ± 10 60 ± 4 *
IFN-γ 2 ± 0 724 ± 118 *
IL-1β 113 ± 25 156 ± 8
IL-2 55 ± 2 56 ± 1
IL-3 2 ± 0 3 ± 2
IL-4 3 ± 1 9 ± 1
IL-5 23 ± 12 193 ± 23 *
IL-6 184 ± 17 2217 ± 54 *
IL-7 16 ± 4 26 ± 5
IL-9 339 ± 43 246 ± 37
IL-12(p40) 98 ± 21 93 ± 14
IL-12(p70) 29 ± 16 39 ± 4
IL-13 15 ± 11 168 ± 20 *
IL-15 7 ± 4 33 ± 4 *
IL-17 10 ± 3 44 ± 4 *
IP-10 93 ± 11 6177 ± 2355
MIP-2 18 ± 13 921 ± 137 *
KC 67 ± 13 1983 ± 339 *
LIF 2 ± 0 172 ± 21 *
LIX 177 ± 31 262 ± 15
MCP-1 84 ± 16 2113 ± 184 *
MIP-1α 30 ± 7 460 ± 74 *
MIP-1β 2 ± 0 560 ± 122 *
MIG 669 ± 6 OORb,*
RANTES 74 ± 7 281 ± 21 *
TNF-α 3 ± 1 106 ± 15 *
VEGF 34 ± 10 56 ± 9
a
10 µg OVA and 107 GE VRP.
b
Out of range (10,000 pg/ml used for calculation of significance)
*
Levels are significantly affected by VRP (p<0.05)
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